PHR Phreesia, Inc.
NYSE · SEC CIK 1412408 · EDGAR
- Bought, last 12 months
- $28.77M 2 purchases by 2 insiders
- Sold, last 12 months
- $2.18M 37 sales by 8 insiders
- Filings on record
- 566 since 2021-07-12, latest 2026-09-22 16:34
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Pale Fire Capital SICAV a.s. | 10% | $18.30M | — |
| Pale Fire Capital SE | 10% | $10.46M | — |
| Hoffman Allison C | GC, Sec | — | $537.1K |
| Indig Chaim | CEO, Dir | — | $421.0K |
| Linetsky David | Pres, Network Solutions | — | $347.2K |
| Gandhi Balaji | CFO | — | $291.8K |
| Roberts Evan | Pres, Provider Solutions | — | $281.9K |
| Hui Yvonne | Principal Accounting Off | — | $168.5K |
| VanDuyn Amy Beth | SVP, Human Resources | — | $105.8K |
| Egbuonu-Davis Lisa | Dir | — | $30.0K |
Transactions 672
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-20 | 2025-02-18 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $29.72 | -3,496 | 142.6K | -2% | -$103.9K | |
| M | 2025-02-20 | 2025-02-18+ | PHR | Roberts Evan | COO | S - Sale | $30.06 | -3,696 | 741.0K | -0.5% | -$111.1K |
| M | 2025-02-20 | 2025-02-18+ | PHR | Gandhi Balaji | CFO | S - Sale | $30.04 | -5,867 | 105.4K | -5% | -$176.2K |
| 2025-02-18 | 2025-02-13 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $29.70 | -11.6K | 218.1K | -5% | -$345.0K | |
| M | 2025-02-18 | 2025-02-13+ | PHR | Roberts Evan | COO | S - Sale | $30.02 | -19.6K | 744.7K | -3% | -$588.2K |
| M | 2025-02-18 | 2025-02-13+ | PHR | Gandhi Balaji | CFO | S - Sale | $30.01 | -33.6K | 116.2K | -22% | -$1.01M |
| 2025-02-11 | 2025-02-07 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $29.52 | -300 | 229.8K | -0.1% | -$8,856 | |
| 2025-02-07 | 2025-02-05 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $29.50 | -720 | 230.1K | -0.3% | -$21.2K | |
| 2025-02-04 | 2025-01-31 | PHR | Munson Gillian | Dir | A - Grant | $28.46 | +351 | 37.1K | +1.0% | +$9,989 | |
| 2025-02-04 | 2025-01-31 | PHR | CAHILL EDWARD L | Dir | A - Grant | $28.46 | +351 | 47.4K | +0.7% | +$9,989 | |
| 2025-02-04 | 2025-01-31 | PHR | Goldstein Lainie | Dir | A - Grant | $28.46 | +351 | 41.5K | +0.9% | +$9,989 | |
| 2025-01-31 | 2025-01-29 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $29.68 | -500 | 230.8K | -0.2% | -$14.8K | |
| M | 2025-01-29 | 2025-01-27 | PHR | Gandhi Balaji | CFO | S - Sale | $27.47 | -4,813 | 144.9K | -3% | -$132.2K |
| M | 2025-01-29 | 2025-01-27 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $27.47 | -3,475 | 115.8K | -3% | -$95.5K |
| M | 2025-01-29 | 2025-01-27 | PHR | Indig Chaim | CEO, Dir | S - Sale | $27.47 | -26.2K | 1.26M | -2% | -$721.1K |
| M | 2025-01-29 | 2025-01-27+ | PHR | Hoffman Allison C | GC, Sec | S - Sale | $27.97 | -12.8K | 154.3K | -8% | -$357.8K |
| M | 2025-01-29 | 2025-01-27 | PHR | Roberts Evan | COO | S - Sale | $27.47 | -10.7K | 764.3K | -1% | -$294.4K |
| M | 2025-01-29 | 2025-01-27 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $27.47 | -11.7K | 231.3K | -5% | -$321.0K |
| 2025-01-27 | 2025-01-24 | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $28.00 | -127 | 25.6K | -0.5% | -$3,556 | |
| 2025-01-24 | 2025-01-23 | PHR | Hoffman Allison C | GC, Sec | A - Grant | $0.00 | +12.8K | 158.9K | +9% | $0 | |
| 2025-01-24 | 2025-01-23 | PHR | Gandhi Balaji | CFO | A - Grant | $0.00 | +7,900 | 149.7K | +6% | $0 | |
| 2025-01-24 | 2025-01-23 | PHR | Roberts Evan | COO | A - Grant | $0.00 | +19.6K | 775.0K | +3% | $0 | |
| 2025-01-24 | 2025-01-23 | PHR | Linetsky David | SVP, Life Sciences | A - Grant | $0.00 | +19.6K | 243.0K | +9% | $0 | |
| 2025-01-24 | 2025-01-23 | PHR | Indig Chaim | CEO, Dir | A - Grant | $0.00 | +48.9K | 1.29M | +4% | $0 | |
| 2025-01-24 | 2025-01-23 | PHR | VanDuyn Amy Beth | SVP, Human Resources | A - Grant | $0.00 | +7,900 | 118.2K | +7% | $0 | |
| 2025-01-22 | 2025-01-21 | PHR | Indig Chaim | CEO, Dir | S - Sale | $27.31 | -21.7K | 1.24M | -2% | -$592.4K | |
| 2025-01-22 | 2025-01-21 | PHR | Gandhi Balaji | CFO | S - Sale | $27.31 | -5,827 | 141.8K | -4% | -$159.1K | |
| 2025-01-22 | 2025-01-21 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $27.31 | -4,720 | 110.3K | -4% | -$128.9K | |
| 2025-01-22 | 2025-01-21 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $27.31 | -13.9K | 223.4K | -6% | -$378.9K | |
| 2025-01-22 | 2025-01-21 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $27.31 | -8,426 | 146.1K | -5% | -$230.1K | |
| 2025-01-22 | 2025-01-21 | PHR | Roberts Evan | COO | S - Sale | $27.31 | -12.7K | 755.5K | -2% | -$348.2K | |
| M | 2025-01-17 | 2025-01-15 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $26.90 | -4,585 | 155.6K | -3% | -$123.3K |
| 2025-01-17 | 2025-01-15 | PHR | Indig Chaim | CEO, Dir | S - Sale | $26.98 | -2,990 | 1.26M | -0.2% | -$80.7K | |
| 2025-01-17 | 2025-01-15 | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $26.87 | -381 | 25.8K | -1% | -$10.2K | |
| 2025-01-17 | 2025-01-15 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $26.98 | -604 | 115.0K | -0.5% | -$16.3K | |
| 2025-01-17 | 2025-01-15 | PHR | Gandhi Balaji | CFO | S - Sale | $26.98 | -836 | 147.7K | -0.6% | -$22.6K | |
| 2025-01-17 | 2025-01-15 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $26.98 | -1,946 | 237.3K | -0.8% | -$52.5K | |
| 2025-01-17 | 2025-01-15 | PHR | Roberts Evan | COO | S - Sale | $26.98 | -1,785 | 768.2K | -0.2% | -$48.2K | |
| 2025-01-16 | 2025-01-14 | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $26.38 | -362 | 26.2K | -1% | -$9,550 | |
| 2025-01-13 | 2025-01-10 | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $27.85 | -388 | 26.5K | -1% | -$10.8K | |
| M | 2025-01-10 | 2025-01-08 | PHR | Roberts Evan | COO | S - Sale | $27.95 | -2,681 | 770.0K | -0.3% | -$74.9K |
| 2025-01-10 | 2025-01-08 | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $28.00 | -288 | 26.9K | -1% | -$8,064 | |
| 2025-01-08 | 2025-01-06 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $26.61 | -3,982 | 159.1K | -2% | -$106.0K | |
| 2025-01-08 | 2025-01-06 | PHR | Indig Chaim | CEO, Dir | S - Sale | $26.61 | -5,375 | 1.26M | -0.4% | -$143.0K | |
| M | 2025-01-08 | 2025-01-06+ | PHR | Roberts Evan | COO | S - Sale | $26.89 | -10.2K | 780.0K | -1% | -$274.1K |
| 2025-01-08 | 2025-01-06 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $26.61 | -3,133 | 239.2K | -1% | -$83.4K | |
| 2025-01-08 | 2025-01-06 | PHR | Gandhi Balaji | CFO | S - Sale | $26.61 | -3,195 | 148.5K | -2% | -$85.0K | |
| 2025-01-08 | 2025-01-06 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $26.61 | -1,311 | 115.6K | -1% | -$34.9K | |
| 2025-01-06 | 2025-01-02 | PHR | Indig Chaim | CEO, Dir | A - Grant | $0.00 | +46.9K | 1.27M | +4% | $0 | |
| 2025-01-06 | 2025-01-02 | PHR | Linetsky David | SVP, Life Sciences | A - Grant | $0.00 | +54.0K | 242.3K | +29% | $0 | |
| 2025-01-06 | 2025-01-02 | PHR | Hoffman Allison C | GC, Sec | A - Grant | $0.00 | +46.5K | 163.1K | +40% | $0 | |
| 2025-01-06 | 2025-01-02 | PHR | Roberts Evan | COO | A - Grant | $0.00 | +54.0K | 782.9K | +7% | $0 | |
| 2025-01-06 | 2025-01-02 | PHR | Gandhi Balaji | CFO | A - Grant | $0.00 | +54.0K | 151.7K | +55% | $0 | |
| 2025-01-06 | 2025-01-02 | PHR | VanDuyn Amy Beth | SVP, Human Resources | A - Grant | $0.00 | +23.5K | 116.9K | +25% | $0 | |
| 2025-01-03 | 2024-12-31 | PHR | Hoffman Allison C | GC, Sec | A - Grant | $17.57 | +298 | 116.6K | +0.3% | +$5,236 | |
| 2025-01-03 | 2024-12-31 | PHR | Hui Yvonne | Principal Accounting Off | A - Grant | $17.57 | +388 | 27.2K | +1% | +$6,817 | |
| 2024-12-19 | 2024-12-18 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $24.88 | -3,495 | 116.3K | -3% | -$87.0K | |
| I | 2024-12-19 | 2024-12-18 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $25.38 | -24 | 8,851 | -0.3% | -$609.12 |
| MI | 2024-12-18 | 2024-12-16+ | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $25.00 | -96 | 8,875 | -1% | -$2,400 |
| DM | 2024-12-17 | 2024-12-13+ | PHR | Weintraub Michael | Dir | S - Sale+OE | $25.05 | -21.4K | 242.8K | -8% | -$536.7K |
| DM | 2024-12-17 | 2024-12-13+ | PHR | Weintraub Michael | Dir | M - OptEx | $4.71 | +21.4K | 243.7K | +10% | +$100.9K |
| 2024-12-13 | 2024-12-11 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $24.85 | -11.9K | 188.4K | -6% | -$294.5K | |
| D | 2024-12-13 | 2024-12-11 | PHR | Weintraub Michael | Dir | M - OptEx | $4.71 | +18.6K | 261.4K | +8% | +$87.5K |
| D | 2024-12-13 | 2024-12-11 | PHR | Weintraub Michael | Dir | S - Sale+OE | $25.10 | -18.6K | 242.8K | -7% | -$466.2K |
| 2024-12-12 | 2024-12-10 | PHR | Roberts Evan | COO | S - Sale | $24.09 | -25.0K | 728.9K | -3% | -$602.2K | |
| 2024-12-05 | 2024-12-03 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $20.93 | -25.4K | 93.5K | -21% | -$532.6K | |
| D | 2024-12-04 | 2024-12-02 | PHR | Weintraub Michael | Dir | S - Sale+OE | $21.01 | -15.2K | 242.8K | -6% | -$318.3K |
| D | 2024-12-04 | 2024-12-02 | PHR | Weintraub Michael | Dir | M - OptEx | $2.03 | +15.2K | 258.0K | +6% | +$30.8K |
| 2024-11-01 | 2024-10-31 | PHR | CAHILL EDWARD L | Dir | A - Grant | $18.29 | +546 | 47.0K | +1% | +$9,986 | |
| 2024-11-01 | 2024-10-31 | PHR | Munson Gillian | Dir | A - Grant | $18.29 | +546 | 36.7K | +2% | +$9,986 | |
| 2024-11-01 | 2024-10-31 | PHR | Goldstein Lainie | Dir | A - Grant | $18.29 | +546 | 41.1K | +1% | +$9,986 | |
| 2024-10-22 | 2024-10-18 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $20.49 | -1,100 | 200.2K | -0.5% | -$22.5K | |
| 2024-10-17 | 2024-10-15 | PHR | Indig Chaim | CEO, Dir | S - Sale | $21.03 | -3,089 | 1.22M | -0.3% | -$65.0K | |
| 2024-10-17 | 2024-10-15 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $21.03 | -1,212 | 119.8K | -1% | -$25.5K | |
| M | 2024-10-17 | 2024-10-15+ | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $20.98 | -3,214 | 26.8K | -11% | -$67.4K |
| 2024-10-17 | 2024-10-15 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $21.03 | -2,011 | 201.3K | -1.0% | -$42.3K | |
| 2024-10-17 | 2024-10-15 | PHR | Roberts Evan | COO | S - Sale | $21.03 | -1,843 | 753.9K | -0.2% | -$38.8K | |
| 2024-10-17 | 2024-10-15 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $21.03 | -624 | 118.9K | -0.5% | -$13.1K | |
| 2024-10-17 | 2024-10-15 | PHR | Gandhi Balaji | CFO | S - Sale | $21.03 | -864 | 97.7K | -0.9% | -$18.2K | |
| I | 2024-09-20 | 2024-09-19 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $24.04 | -24 | 8,971 | -0.3% | -$576.96 |
| MI | 2024-09-19 | 2024-09-17+ | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $24.34 | -97 | 8,995 | -1% | -$2,361 |
| 2024-09-13 | 2024-09-12 | PHR | Egbuonu-Davis Lisa | Dir | S - Sale | $23.03 | -1,400 | 18.1K | -7% | -$32.2K | |
| 2024-09-12 | 2024-09-10 | PHR | Roberts Evan | COO | S - Sale | $23.25 | -3,148 | 755.7K | -0.4% | -$73.2K | |
| M | 2024-09-12 | 2024-09-10+ | PHR | Hoffman Allison C | GC, Sec | S - Sale | $23.30 | -4,694 | 123.1K | -4% | -$109.4K |
| 2024-09-12 | 2024-09-10 | PHR | Gandhi Balaji | CFO | S - Sale | $23.25 | -3,502 | 98.6K | -3% | -$81.4K | |
| 2024-09-12 | 2024-09-10 | PHR | Hui Yvonne | Principal Accounting Off | S - Sale | $23.25 | -744 | 30.0K | -2% | -$17.3K | |
| I | 2024-09-12 | 2024-09-10 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $23.25 | -95 | 9,092 | -1% | -$2,209 |
| 2024-09-12 | 2024-09-10 | PHR | Linetsky David | SVP, Life Sciences | S - Sale | $23.25 | -1,716 | 203.3K | -0.8% | -$39.9K | |
| 2024-09-12 | 2024-09-10 | PHR | Indig Chaim | CEO, Dir | S - Sale | $23.25 | -5,295 | 1.22M | -0.4% | -$123.1K | |
| 2024-09-12 | 2024-09-10 | PHR | VanDuyn Amy Beth | SVP, Human Resources | S - Sale | $23.25 | -737 | 119.5K | -0.6% | -$17.1K | |
| 2024-09-10 | 2024-09-06 | PHR | VanDuyn Amy Beth | SVP, Human Resources | A - Grant | — | +1,642 | 120.3K | +1% | — | |
| 2024-09-10 | 2024-09-06 | PHR | Roberts Evan | COO | A - Grant | — | +5,633 | 758.9K | +0.7% | — | |
| 2024-09-10 | 2024-09-06 | PHR | Hui Yvonne | Principal Accounting Off | A - Grant | — | +2,049 | 30.8K | +7% | — | |
| 2024-09-10 | 2024-09-06 | PHR | Indig Chaim | CEO, Dir | A - Grant | — | +9,670 | 1.23M | +0.8% | — | |
| I | 2024-09-10 | 2024-09-06 | PHR | Linetsky David | SVP, Life Sciences | A - Grant | — | +234 | 9,187 | +3% | — |
| 2024-09-10 | 2024-09-06 | PHR | Linetsky David | SVP, Life Sciences | A - Grant | — | +2,816 | 205.0K | +1% | — | |
| 2024-09-10 | 2024-09-06 | PHR | Gandhi Balaji | CFO | A - Grant | — | +5,633 | 102.1K | +6% | — | |
| 2024-09-10 | 2024-09-06 | PHR | Hoffman Allison C | GC, Sec | A - Grant | — | +4,694 | 125.7K | +4% | — | |
| 2024-08-28 | 2024-08-26 | PHR | Hoffman Allison C | GC, Sec | S - Sale | $26.03 | -14.1K | 121.0K | -10% | -$367.3K | |
| I | 2024-08-16 | 2024-08-15 | PHR | Linetsky David | SVP, Life Sciences | A - Grant | $0.00 | +2,000 | 8,953 | +29% | $0 |
Purchase Sale Sale after option exercise All abbreviations